Work

Supplemental Figure 1 from Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients

Year: 2023

Type: supplementary-materials

Abstract: Supplemental Figure 1: Quantitative concordance between NGS and ddPCR KRASG12C results.ctDNA, circulating tumor DNA; ddPCR, droplet digital polymerase chain reaction.

DOI: 10.1158/1078-0432.23952195

Authors: Cloud P. Paweletz, Grace A. Heavey, Yanan Kuang, Emily Durlacher, Thian Kheoh, Richard C. Chao, Alexander I. Spira, Konstantinos Leventakos, Melissa L. Johnson, Sai-Hong Ignatius Ou, Gregory J. Riely, Kenna Anderes, Wenjing Yang, James G. Christensen, Pasi A. Jänne

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4385838628

Cites:

Cited by:

Related to: 10